BioVie Inc. has completed enrollment of 60 patients in its Phase 2 SUNRISE-PD trial evaluating bezisterim for early-stage Parkinson’s disease. All participants were diagnosed within the last four years and are levodopa-naïve, positioning the study to assess the investigational therapy’s impact on disease progression. The company expects to report top-line data in the fourth quarter, which will include assessments of motor function scales and biomarkers of neurodegeneration.

On Wednesday, trading volume in BioVie shares fell by 35% compared with its 122,030-share daily average, with approximately 79,600 shares changing hands. The decline in liquidity underscores a period of consolidation following the recent enrollment announcement and highlights investor focus on upcoming clinical readouts rather than short-term market movements.

Research firms have issued divergent ratings: one house upgraded its view from Sell to Hold, while another reaffirmed a Sell (e+) stance. Consensus from MarketBeat places BioVie at a Moderate Buy, reflecting a split outlook among analysts. The firm’s negative trailing price-to-earnings ratio and recent earnings miss—reported loss per share of $0.98 versus estimates of $0.79—have contributed to the cautious stance.

Recent SEC filings show that Prelude Capital Management, Prosperity Wealth Management, Citadel Advisors, Jane Street Group and XTX Topco collectively injected over $800,000 into new BioVie positions during the second and third quarters. Institutional ownership now stands at 4.59% of outstanding shares, indicating growing confidence in the company’s lead programs despite current market skepticism.